Baseline patient characteristics
| . | No. of patients . |
|---|---|
| Total number of patients treated | 33 |
| Sex | |
| Male | 17 (52) |
| Female | 16 (48) |
| Age at study enrollment, median (range), y | 58 (22-74) |
| Diagnosis | |
| AML | 22 (67) |
| MDS | 6 (18) |
| ALL | 2 (1) |
| MM | 2 (1) |
| DLBCL | 1 (0) |
| Time since prior allo-HCT to first dose of ALT-803, median (range), d | 292 (88-2843) |
| Donor relationship | |
| Matched related | 13 (39) |
| Matched unrelated | 7 (21) |
| Unrelated cord blood | 9 (27) |
| Haploidentical related | 4 (12) |
| Conditioning regimen | |
| Myeloablative | 15 (45) |
| Reduced intensity | 18 (55) |
| Prior history of GVHD | |
| Grade I-II, acute | 7 (21) |
| Grade III-IV, acute | 1 (0) |
| All grades, chronic | 1 (0) |
| Moderate to severe, chronic | 0 (0) |
| Donor cell engraftment at the time of enrollment, median (range), % | 57 (25-100) |
| Disease status at enrollment | |
| First relapse | 11 (33) |
| Second relapse | 8 (24) |
| Third relapse | 7 (21) |
| Transplant to time of relapse, median (range), d | 187 (21-2751) |
| Transplant to first dose of ALT-803, median (range), d | 257 (88-2843) |
| . | No. of patients . |
|---|---|
| Total number of patients treated | 33 |
| Sex | |
| Male | 17 (52) |
| Female | 16 (48) |
| Age at study enrollment, median (range), y | 58 (22-74) |
| Diagnosis | |
| AML | 22 (67) |
| MDS | 6 (18) |
| ALL | 2 (1) |
| MM | 2 (1) |
| DLBCL | 1 (0) |
| Time since prior allo-HCT to first dose of ALT-803, median (range), d | 292 (88-2843) |
| Donor relationship | |
| Matched related | 13 (39) |
| Matched unrelated | 7 (21) |
| Unrelated cord blood | 9 (27) |
| Haploidentical related | 4 (12) |
| Conditioning regimen | |
| Myeloablative | 15 (45) |
| Reduced intensity | 18 (55) |
| Prior history of GVHD | |
| Grade I-II, acute | 7 (21) |
| Grade III-IV, acute | 1 (0) |
| All grades, chronic | 1 (0) |
| Moderate to severe, chronic | 0 (0) |
| Donor cell engraftment at the time of enrollment, median (range), % | 57 (25-100) |
| Disease status at enrollment | |
| First relapse | 11 (33) |
| Second relapse | 8 (24) |
| Third relapse | 7 (21) |
| Transplant to time of relapse, median (range), d | 187 (21-2751) |
| Transplant to first dose of ALT-803, median (range), d | 257 (88-2843) |
Values are reported as n (%) of patients unless indicated otherwise.
ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma.